CAJ | 학술논문

过去的二十年里，进展期胃癌患者通过治疗后可以改善生活质量及延长生存期，但是其治疗方法并没有获得显著进展。虽然胃癌的中位生存期大约在7～11个月，且存活超过2年的已经＞10%，但是，对于进展期胃癌患者来说，其最合适的一线化疗方案一直存在争议，且大多数人对化疗仍持有偏见。最近，肿瘤生物学的显著进展促进了靶向致癌关键途径的新药物研究。在国际随机研究中，对进展期胃癌来说，多数分子靶向因子被证实有效，一种抗HER-2单克隆抗体（曲妥珠单抗）显示在抗HER-2阳性的进展期胃癌方面有抗肿瘤活性。然而，只有20%的HER-2阳性的进展期胃癌患者在此获益。因此，发展更有效的因子和鉴别预测及预后的标记物因子来选择哪些患者能从特定的化疗方案和靶向治疗中获益显得至关重要。本文就进展期胃癌的靶向治疗作一综述。
과거적이십년리，진전기위암환자통과치료후가이개선생활질량급연장생존기，단시기치료방법병몰유획득현저진전。수연위암적중위생존기대약재7～11개월，차존활초과2년적이경＞10%，단시，대우진전기위암환자래설，기최합괄적일선화료방안일직존재쟁의，차대다수인대화료잉지유편견。최근，종류생물학적현저진전촉진료파향치암관건도경적신약물연구。재국제수궤연구중，대진전기위암래설，다수분자파향인자피증실유효，일충항HER-2단극륭항체（곡타주단항）현시재항HER-2양성적진전기위암방면유항종류활성。연이，지유20%적HER-2양성적진전기위암환자재차획익。인차，발전경유효적인자화감별예측급예후적표기물인자래선택나사환자능종특정적화료방안화파향치료중획익현득지관중요。본문취진전기위암적파향치료작일종술。
Although medical treatment has been shown to improve quality of life and prolong survival, no significant progress has been made in the treatment of advanced gastric cancer (AGC) within the last two decades. Thus the optimum standard first-line chemotherapy regimen for AGC remains debatable: and most responses to chemotherapy are partial and of short duration; the median survival is approximately 7 to 11 months, and survival rate at 2 years is exceptionally>10%. Recently, remarkable progress in tumor biology has led to the development of new agents that target critical aspects of oncogenic pathways. For AGC, many molecular targeting agents have been evaluated in international randomized studies, and trastuzumab (an anti-HER-2 monoclonal antibody) has shown antitumor activity against HER-2-positive AGC. However, this benefit is limited to only 20% patients with AGC (patients with HER-2-positive AGC). Therefore, there remains a critical need for both the development of more effective agents and the identification of molecular predictive and prognostic markers to select those patients who will benefit most from specific chemotherapeutic regimens and targeted therapies. This article reviewed the targeted therapy for advanced gastric cancer.